Male contraceptive historical perspective

Jump to navigation Jump to search

Male contraceptive Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Male contraceptive historical perspective On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Male contraceptive historical perspective

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Male contraceptive historical perspective

CDC on Male contraceptive historical perspective

Male contraceptive historical perspective in the news

Blogs on Male contraceptive historical perspective

Directions to Hospitals Treating Male contraceptive

Risk calculators and risk factors for Male contraceptive historical perspective

Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.

Abandoned research

  • Gossypol, derived from cotton seeds, was used in trials by the Chinese government for about fifteen years. While it was found to be a reliable contraceptive, it has serious health effects, and ten to twenty percent of users become permanently sterile. Research on it as a temporary contraceptive has been abandoned.
  • Zavesca (aka Miglustat or NB-DNJ) is a drug approved for treatment of several rare lipid storage disorder diseases. In mice, it provided effective and fully reversible contraception. But it seems this effect was only true for several genetically related strains of laboratory mice. Zavesca showed no contraceptive effect in other mammals.[1]

References

  1. Amory JK, Muller CH, Page ST, Leifke E, Pagel ER, Bhandari A, Subramanyam B, Bone W, Radlmaier A, Bremner WJ. Miglustat has no apparent effect on spermatogenesis in normal men. Human Reproduction advance access 25 October 2006.


Template:WikiDoc Sources